MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.400 -0.020 (-1.41%)
Official Closing Price Updated: 8:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Regulatory Approval for Phase II Ebola Trial of NV-387 Oral Gummies
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
From NanoViricides
Via ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Approximately $3.8 Million Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Seeks Approval to Launch Phase II Ebola Trial in DRC
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Ethics Approval for Phase II Ebola Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
From NanoViricides
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Coverage Initiated With Outperform Rating, $6 Price Target
Via Investor Brand Network
Topics Intellectual Property
News headline image
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
From NanoViricides
Via ACCESS Newswire
News headline image
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Ships NV-387 Drug Supply to DRC for Phase II MPox Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
From NanoViricides
Via ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Receives DRC Approval to Advance Proposed Phase II Ebola Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
Via ACCESS Newswire
News headline image
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
Via Investor Brand Network
Topics Intellectual Property
News headline image
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $2 Million Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
Via Investor Brand Network
Topics Intellectual Property
News headline image
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Development Across Multiple Viral Disease Targets
Via Investor Brand Network
Topics Intellectual Property
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Prices $2 Million Registered Direct Offering
Via Investor Brand Network
News headline image
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Via ACCESS Newswire
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story